30
Participants
Start Date
January 31, 2011
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
Intravitreal injection of pegaptanib sodium
Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen \[TM\]) 0.3mg every 6 weeks over a 30 week period.
Oxford Eye Hospital, Oxford
Collaborators (1)
Pfizer
INDUSTRY
University of Oxford
OTHER